News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Policy
Ranbaxy Laboratories Gains in Mumbai After U.S. Withdraws Motion
October 9, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Oct. 8 (Bloomberg) -- Ranbaxy Laboratories Ltd., the Indian drugmaker being purchased by Japan's Daiichi Sankyo Co., rose the most in almost three months after the U.S. withdrew a motion seeking to force the company to turn over audit reports.
Twitter
LinkedIn
Facebook
Email
Print
Legal
Regulatory
Asia
MORE ON THIS TOPIC
FDA
Makary Discusses Expedited Rare Disease Approvals Pathway, ‘Public Distrust’ in New Interview
April 21, 2025
·
2 min read
·
Tristan Manalac
FDA
FDA’s User Fee Negotiation Teams Gutted by Layoffs: Reuters
April 18, 2025
·
2 min read
·
Tristan Manalac
FDA
FDA Moves to Restrict Industry Influence on Advisory Committees
April 18, 2025
·
2 min read
·
Tristan Manalac
Editorial
Here Today, Gone Tomorrow: Trump’s Policies Give Biopharma Whiplash
April 18, 2025
·
4 min read
·
Jef Akst